PTPN3 inhibition contributes to the activation of the dendritic cell function to be a promising new immunotherapy target

Iwamoto, Naoya; Onishi, Hideya; Masuda, Shogo; Imaizumi, Akira; Sakanashi, Keita; Morisaki, Shinji; Nagao, Shinjiro; Koga, Shozo; Ozono, Keigo; Umebayashi, Masayo; Morisaki, T.; Nakamura, Masafumi

doi:10.1007/s00432-023-05250-8

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, reports have suggested that shRNA-mediated knockdown of PTPN3 enhances human T cell responses to ovarian cancer [99] and small-cell lung carcinoma [100] xenografts in mice. PTPN3 may also negatively regulate dendritic cell function in cancer [101] and has tumour-suppressor activity, which is independent of phosphatase activity, by potentiating TGFβ-driven growth inhibitory responses in HCC cell lines [102].…”

Section: Ptpn3 Ptpn4 and Ptpn13mentioning

confidence: 99%

Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Salmond

2024

Cells

View full text Add to dashboard Cite

Advances in immunotherapy have brought significant therapeutic benefits to many cancer patients. Nonetheless, many cancer types are refractory to current immunotherapeutic approaches, meaning that further targets are required to increase the number of patients who benefit from these technologies. Protein tyrosine phosphatases (PTPs) have long been recognised to play a vital role in the regulation of cancer cell biology and the immune response. In this review, we summarize the evidence for both the pro-tumorigenic and tumour-suppressor function of non-receptor PTPs in cancer cells and discuss recent data showing that several of these enzymes act as intracellular immune checkpoints that suppress effective tumour immunity. We highlight new data showing that the deletion of inhibitory PTPs is a rational approach to improve the outcomes of adoptive T cell-based cancer immunotherapies and describe recent progress in the development of PTP inhibitors as anti-cancer drugs.

show abstract

Section: Ptpn3 Ptpn4 and Ptpn13mentioning

confidence: 99%

Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Salmond

2024

Cells

View full text Add to dashboard Cite

show abstract

PTPN3 inhibition contributes to the activation of the dendritic cell function to be a promising new immunotherapy target

Cited by 1 publication

References 26 publications

Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Contact Info

Product

Resources

About